Close
Close

Anti-Human NKG2D (XW-588)-28Z CAR IVT mRNA (XS-0822-YF4268)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

In vitro transcription (IVT) is the synthesis of RNA molecules. Creative Biolabs produces CAR mRNAs with our proprietary production platform, ensuring the quality and expression efficiency. This product is anti-NKG2D scFv (XW-588)-28Z chimeric antigen receptor (CAR) mRNA which can be used for CAR expression in various immune cells.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

CAR Information

  • Target Species
  • Human
  • Clone
  • XW-588
  • Host
  • Human
  • CAR Construction
  • scFv-CD28-CD3ζ
  • CAR Generation
  • Second
  • CAR Signaling Description
  • CD28
    CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide co-stimulatory signals required for T cell activation and survival. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells (APC). CD28 modulates the primary TCR/CD3ζ signal in a different fashion than the late costimulatory elements OX40 and 4-1BB. CD28 enhances the expression of downstream regulators that impact on T-cell proliferation, death, differentiation, and effector functions. CAR+ T cells containing the CD28 endodomain showed strikingly enhanced sustained T cell activation, growth, survival. And CD28 results in a brightly expressed, stable receptor as the transmembrane domain. Including CD28 costimulatory domains in CARs led to enhanced anti-malignancy efficacy.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

CAR mRNA Properties

  • Cap
  • Cap 1
  • PolyA
  • Segmented PolyA
  • Product Type
  • CAR IVT mRNA
  • Concentration
  • Lot specific
  • Buffer
  • 1 mM Sodium citrate (pH 6.4)
  • Storage
  • Aliquot and store at -80°C. Avoid freeze/thaw cycles.
  • Handling
  • Thaw and work with mRNA on ice. Upon first use, pulse spin before opening and aliquot into single use portions. DO NOT vortex. Use only certified RNase-free reagents and consumables with proper RNase-free technique. Use of barrier tips is recommended. Avoid freeze/thaw cycles. DO NOT mix with media containing serum unless first complexed with a stabilizing transfection reagent.

mRNA Quality Control

  • OD260/280
  • PASS
  • Agarose Gel Mobility
  • PASS
  • IVT Vector Sequencing
  • PASS
  • IVT Vector Enzyme Digestion
  • PASS
  • mRNA Transfection Efficiency
  • PASS
  • CAR Expression after mRNA Transfection
  • PASS

Target Information

  • Target
  • NKG2D
  • Gene Name
  • KLRK1
  • Full Name
  • killer cell lectin like receptor K1
  • Introduction
  • Natural killer (NK) cells are lymphocytes that can mediate lysis of certain tumor cells and virus-infected cells without previous activation. They can also regulate specific humoral and cell-mediated immunity. NK cells preferentially express several calcium-dependent (C-type) lectins, which have been implicated in the regulation of NK cell function. The NKG2 gene family is located within the NK complex, a region that contains several C-type lectin genes preferentially expressed in NK cells. This gene encodes a member of the NKG2 family. The encoded transmembrane protein is characterized by a type II membrane orientation (has an extracellular C terminus) and the presence of a C-type lectin domain. It binds to a diverse family of ligands that include MHC class I chain-related A and B proteins and UL-16 binding proteins, where ligand-receptor interactions can result in the activation of NK and T cells. The surface expression of these ligands is important for the recognition of stressed cells by the immune system, and thus this protein and its ligands are therapeutic targets for the treatment of immune diseases and cancers. Read-through transcription exists between this gene and the upstream KLRC4 (killer cell lectin-like receptor subfamily C, member 4) family member in the same cluster.
  • Related Diseases
  • Colorectal cancer
  • Alternative Names
  • KLR; CD314; NKG2D; NKG2-D; D12S2489E

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-Human NKG2D (XW-588) h(CD28-CD3ζ) CAR IVT mRNA (XS-0822-YF4268). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

CAR Vector Products

CAR-MA Cell Products

CAR Cell Products

CAR-MA Vector Products

CAR Viral Particles

AbTCR Vector Products

CAR mRNA

TriCAR Vector Products

Online Inquiry
Products
Global Services
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.
Copyright © 2024 Creative Biolabs. All Rights Reserved
Cart
    Go to checkout